Table 2. Landmark analysis for clinical outcomes between 3- and 5-year follow-up.
| Between 3 and 4 years | Between 4 and 5 years | |||||||
|---|---|---|---|---|---|---|---|---|
| Absorb BVS (n=924) | XIENCE EES (n=921) |
Hazard ratio (95% CI) |
p-value¶ | Absorb BVS (n=924) | XIENCE EES (n=921) | Hazard ratio (95% CI) | p-value¶ | |
| All-cause death | 14 (1.6%) | 18 (2.1%) | 0.77 (0.38-1.54) | 0.453 | 16 (2.0%) | 17 (2.2%) | 0.93 (0.47-1.83) | 0.828 |
| Cardiac death | 4 (0.5%) | 7 (0.8%) | 0.56 (0.16-1.92) | 0.354 | 6 (0.7%) | 8 (1.1%) | 0.74 (0.26-2.13) | 0.574 |
| Cardiovascular death | 5 (0.6%) | 9 (1.1%) | 0.55 (0.18-1.64) | 0.274 | 9 (1.1%) | 10 (1.3%) | 0.89 (0.36-2.18) | 0.793 |
| All myocardial infarction | 13 (1.6%) | 6 (0.8%) | 2.19 (0.83-5.76) | 0.103 | 8 (1.1%) | 7 (0.9%) | 1.15 (0.42-3.18) | 0.780 |
| Target vessel MI | 9 (1.1%) | 3 (0.4%) | 3.01 (0.82-11.13) | 0.082 | 5 (0.7%) | 6 (0.8%) | 0.83 (0.25-2.73) | 0.763 |
| Non-target vessel MI | 3 (0.4%) | 3 (0.4%) | 0.99 (0.20-4.91) | 0.991 | 3 (0.4%) | 2 (0.3%) | 1.49 (0.25-8.90) | 0.661 |
| Any revascularisation | 26 (3.6%) | 14 (1.9%) | 1.88 (0.98-3.60) | 0.053 | 13 (2.0%) | 18 (2.7%) | 0.74 (0.36-1.50) | 0.399 |
| Target vessel revascularisation | 20 (2.6%) | 5 (0.7%) | 4.01 (1.50-10.68) | 0.003 | 9 (1.3%) | 12 (1.7%) | 0.76 (0.32-1.80) | 0.526 |
| Target lesion revascularisation | 13 (1.6%) | 4 (0.5%) | 3.27 (1.07-10.02) | 0.028 | 6 (0.8%) | 8 (1.1%) | 0.75 (0.26-2.18) | 0.602 |
| Device thrombosis related | 5 (0.6%) | 2 (0.2%) | 2.51 (0.49-12.96) | 0.254 | 3 (0.4%) | 2 (0.3%) | 1.51 (0.25-9.02) | 0.651 |
| Device stenosis related | 11 (1.4%) | 3 (0.4%) | 3.61 (1.01-12.93) | 0.035 | 4 (0.5%) | 6 (0.8%) | 0.66 (0.19-2.33) | 0.514 |
| Composite endpoints | ||||||||
| Target vessel failure | 22 (2.9%) | 12 (1.6%) | 1.85 (0.91-3.73) | 0.082 | 13 (1.8%) | 21 (3.0%) | 0.63 (0.31-1.25) | 0.181 |
| Target lesion failure§ | 16 (2.1%) | 11 (1.4%) | 1.47 (0.68-3.16) | 0.324 | 10 (1.4%) | 18 (2.5%) | 0.56 (0.26-1.21) | 0.136 |
| Patient-oriented composite endpoint‡ | 35 (4.9%) | 30 (4.2%) | 1.19 (0.73-1.94) | 0.481 | 26 (4.0%) | 33 (5.0%) | 0.81 (0.48-1.35) | 0.415 |
| ¶p-values were calculated by the log-rank test. §Composite of cardiac death, target vessel myocardial infarction and target lesion revascularisation. ‡Composite of death, myocardial infarction or any revascularisation. BVS: bioresorbable vascular scaffold; EES: everolimus-eluting stent; MI: myocardial infarction | ||||||||